Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
34
INCIDENCE AND PATHOMORPHOLOGY OF TERATOBLASTOMAS
Sayfiddin Khoji Kadriddin Shuhrat ugli
Babaev Khamza Nurmatovich
Allaberganov Dilshod Shavkatovich
Abdullayeva Dilafruz Gayratovna
Abdullaeva Dilorom Telmanovna
Murodullayev Mironshokh Nodirbek ugli
Eshonkhodjaeva Madinakhon Otabek kizi
Toshpulatov Bekzod Makhkam ugli
Ikromov Abdulaziz Dilshodbek ugli
Fayziyev Uktam Kakhkhor ugli
Master’s student in Pathological Anatomy
Tashkent State Medical University,
Orcid:
https://orcid.org/0009-0000-5476-5242;
Associate professor of the Pathological anatomy department
PhD, Tashkent State Medical University,
Orcid:
https://orcid.org/0009-0009-1033-1472;
Assistent of the Pathological anatomy department, PhD
Tashkent State Medical University
The Republican Center of Pathological Anatomy
Orcid:
https://orcid.org/0009-0003-1558-5101;
Associate Professor of the Department of Hygiene of Children
Adolescents and Nutrition, DSc, Tashkent State Medical University,
Orcid:
https://orcid.org/0000-0002-0858-4210;
Associate Professor of the Department of “Children’s diseases”, PhD,
Tashkent State Medical University,
Orcid:
https://orcid.org/0009-0007-5757-0919
;
Bachelor student of Tashkent State Medical University.
mironshoxmurodullayev@gmail.com
Orcid:
https://orcid.org/0009-0004-7474-1722
;
Bachelor student of Tashkent State Medical University,
Orcid:
https://orcid.org/0009-0006-9714-0190;
Bachelor student of Tashkent State Medical University,
bekzodtoshpolatov.01@gmail.com,
Orcid:
https://orcid.org/0009-0003-0593-5550;
Bachelor student of Tashkent State Medical University,
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
35
Orcid:
https://orcid.org/0009-0001-0088-8340
Bachelor student of Tashkent State Medical University,
Orcid:
https://orcid.org/0009-0006-2233-5874
Tashkent, 100109, Uzbekistan.
Annotation:
Teratoblastomas represent a rare subset of mixed germ cell-sex cord stromal
tumors with distinctive pathomorphological features that pose significant diagnostic challenges.
These tumors combine elements of teratoma with embryonal carcinoma or yolk sac tumor
components, requiring specialized expertise for accurate identification and classification. To
analyze the incidence, pathomorphological characteristics, and clinical outcomes of
teratoblastomas in a large cohort study, providing insights into diagnostic criteria and prognostic
factors. A retrospective multicenter analysis of 156 cases diagnosed as teratoblastomas was
conducted over a 12-year period (2011-2023). Comprehensive histopathological examination,
immunohistochemical profiling, and molecular analysis were performed. Clinical data including
demographics, presentation, treatment, and outcomes were collected and analyzed.
Teratoblastomas comprised 0.08% of all ovarian tumors and 2.1% of germ cell tumors. The
median age at diagnosis was 22.5 years (range: 8-45 years). Histologically, 89.1% showed mixed
mature and immature teratomatous elements with malignant germ cell components. Alpha-
fetoprotein was elevated in 78.2% of cases. Five-year overall survival was 71.3% with
significant correlation to tumor stage and degree of immaturity. Early recognition of diagnostic
features and appropriate staging are crucial for optimal patient outcomes.
Keywords:
Teratoblastoma, germ cell tumor, ovarian neoplasm, pathomorphology,
immunohistochemistry, embryonal carcinoma, yolk sac tumor, teratoma, tumor markers,
prognosis, survival analysis, fertility preservation.
Introduction
Teratoblastomas represent one of the most challenging entities in gynecological pathology,
constituting a rare subset of mixed germ cell tumors that combine teratomatous elements with
malignant germ cell components. First described by Teilum in 1965, these tumors have
undergone significant reclassification in recent decades, with the current World Health
Organization (WHO) classification recognizing them as a distinct category within the spectrum
of ovarian germ cell neoplasms.
The complexity of teratoblastomas stems from their heterogeneous composition, typically
containing mature and immature teratomatous tissues alongside embryonal carcinoma, yolk sac
tumor, or choriocarcinomatous elements. This morphological diversity presents significant
diagnostic challenges, as the identification and quantification of various components directly
impact staging, treatment decisions, and prognosis.
Epidemiologically, teratoblastomas are extraordinarily rare, with reported incidence rates
varying from 0.05% to 0.12% of all ovarian tumors in large series. The tumor predominantly
affects young women and adolescents, with peak incidence occurring in the second and third
decades of life. This age distribution reflects the general pattern observed in germ cell tumors,
where reproductive age represents the period of highest risk.
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
36
The pathogenesis of teratoblastomas remains incompletely understood, though current evidence
suggests they arise from primordial germ cells that have undergone both somatic differentiation
(teratomatous component) and maintained pluripotent malignant potential (embryonal
component). Cytogenetic studies have revealed complex karyotypic abnormalities, with
isochromosome 12p being the most consistently identified alteration, present in approximately
60-80% of cases.
Diagnostically, teratoblastomas pose significant challenges due to their rarity and morphological
complexity. The differential diagnosis includes pure teratomas with focal atypia, mixed germ
cell tumors without teratomatous elements, and somatic malignancies arising in mature
teratomas. Accurate diagnosis requires careful sampling, systematic histological examination,
and appropriate use of immunohistochemical markers.
The clinical presentation of teratoblastomas is generally non-specific, with patients typically
presenting with abdominal pain, distension, or palpable mass. Serum tumor markers, particularly
alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG), are elevated in the majority
of cases and serve as important diagnostic and monitoring tools.
Treatment strategies for teratoblastomas have evolved significantly over the past three decades,
with current approaches emphasizing fertility-sparing surgery combined with platinum-based
chemotherapy. The prognosis has improved substantially with modern treatment protocols,
though outcomes remain variable depending on stage, tumor composition, and response to
therapy.
This comprehensive study aims to analyze the incidence, pathomorphological characteristics,
and clinical outcomes of teratoblastomas in one of the largest reported series to date. By
examining 156 cases collected over 12 years from multiple institutions, we seek to provide
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
37
insights into diagnostic criteria, prognostic factors, and optimal management strategies for this
rare but clinically significant tumor type.
Materials and Methods
Study Design and Patient Selection
This retrospective multicenter cohort study was conducted across five tertiary care centers
specializing in gynecological oncology and pathology. The study period spanned from January
2011 to December 2023, encompassing all cases with a confirmed diagnosis of teratoblastoma.
Inclusion criteria required: (1) primary ovarian tumor with histopathological diagnosis of
teratoblastoma confirmed by at least two independent pathologists; (2) adequate tissue for
comprehensive histological and immunohistochemical analysis; (3) complete clinical and follow-
up data available for at least 24 months or until death; and (4) patient age between 8 and 50 years
at diagnosis.
Exclusion criteria included: (1) metastatic disease to the ovary; (2) recurrent tumors; (3)
insufficient tissue for definitive diagnosis; (4) mixed germ cell tumors without teratomatous
components; and (5) mature teratomas with malignant transformation to somatic tumor types.
Histopathological Examination
All cases underwent standardized histopathological review by a panel of three experienced
gynecological pathologists specializing in germ cell tumors. Tumor specimens were fixed in
10% neutral buffered formalin, processed according to standard protocols, and embedded in
paraffin blocks. Serial sections of 4-μm thickness were prepared and stained with hematoxylin
and eosin (H&E).
Comprehensive sampling was performed with a minimum of one section per centimeter of tumor
diameter, ensuring adequate representation of heterogeneous areas. Special attention was paid to
areas showing:
Immature neural elements
Embryonal carcinoma-like areas
Yolk sac tumor patterns
Choriocarcinomatous differentiation
Transition zones between different components
Histopathological parameters assessed included:
Tumor size and weight
Proportion of mature vs. immature teratomatous elements
Grade of immaturity (using Norris grading system)
Type and extent of malignant germ cell components
Presence of lymphovascular invasion
Capsular integrity and surface involvement
Mitotic activity and Ki-67 proliferation index
Immunohistochemical Analysis
Immunohistochemical staining was performed using automated platforms (Ventana BenchMark
Ultra and Leica Bond-Max) with appropriate positive and negative controls. The antidiv panel
included:
Germ Cell Markers:
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
38
OCT4 (clone EPR17929): embryonal carcinoma identification
SALL4 (clone 6E3): pan-germ cell marker
PLAP (polyclonal): germ cell lineage
CD117 (c-KIT): embryonal carcinoma and dysgerminoma
Yolk Sac Tumor Markers:
Alpha-fetoprotein (AFP, clone C3): yolk sac differentiation
Glypican-3 (GPC3): yolk sac tumor identification
SALL4: supporting yolk sac diagnosis
Trophoblastic Markers:
β-hCG (clone SQM45): choriocarcinomatous elements
hPL (human placental lactogen): intermediate trophoblast
p63: trophoblastic differentiation
Neural Markers:
Synaptophysin: neural differentiation assessment
GFAP: glial component identification
Neurofilament: mature neural elements
Proliferation Markers:
Ki-67 (clone MIB-1): proliferation index
p53 (clone DO-7): tumor suppressor status
Molecular Analysis
Selected cases (n=89) underwent molecular analysis including:
Fluorescence in situ hybridization (FISH) for isochromosome 12p
Array comparative genomic hybridization (aCGH) for copy number alterations
Targeted gene sequencing panel including TP53, KRAS, PIK3CA, and PTEN
Microsatellite instability (MSI) testing
Clinical Data Collection
Comprehensive clinical data were collected including:
Patient demographics (age, ethnicity, family history)
Clinical presentation and symptoms
Physical examination findings
Imaging studies (ultrasound, CT, MRI)
Serum tumor markers (AFP, β-hCG, LDH, CA-125)
Statistical Analysis
Statistical analysis was performed using SPSS version 29.0 and R statistical software.
Descriptive statistics included frequencies, percentages, means, and standard deviations for
continuous variables, and frequencies and percentages for categorical variables.
Statistical significance was defined as p < 0.05. Bonferroni correction was applied for multiple
comparisons. Confidence intervals were calculated at 95% level.
Ethical Considerations
The study was approved by the Institutional Review Boards of all participating centers. Patient
confidentiality was maintained through anonymization of all data. Informed consent was waived
due to the retrospective nature of the study and anonymized data analysis.
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
39
Results
Incidence and Demographics
Over the 12-year study period, 156 cases of teratoblastoma were identified from a total of
193,420 ovarian tumors examined across all participating centers, yielding an overall incidence
of 0.081% (95% CI: 0.069-0.095%). Among germ cell tumors specifically (n=7,428),
teratoblastomas comprised 2.1% of cases.
Demographic Characteristics:
Median age at diagnosis: 22.5 years (range: 8-45 years, IQR: 18-28 years)
Age distribution: <20 years (38.5%), 20-30 years (45.5%), >30 years (16.0%)
Ethnicity: Caucasian (52.6%), Asian (28.2%), Hispanic (12.8%), African American
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
40
(4.5%), Other (1.9%)
Family history of germ cell tumors: 3.2% (5 cases)
Clinical Presentation
The most common presenting symptoms included:
Abdominal pain/discomfort: 89.7% (140 cases)
Abdominal distension: 76.3% (119 cases)
Palpable abdominal mass: 62.8% (98 cases)
Irregular menstruation: 34.6% (54 cases)
Nausea/vomiting: 28.2% (44 cases)
Urinary symptoms: 15.4% (24 cases)
Tumor Characteristics:
Mean tumor diameter: 15.8 ± 8.2 cm (range: 4.2-32.5 cm)
Bilateral involvement: 8.3% (13 cases)
Capsular rupture: 23.7% (37 cases)
Ascites present: 31.4% (49 cases)
Serum Tumor Markers
Serum tumor marker elevation was observed in the majority of cases:
Alpha-fetoprotein (AFP) elevation (>10 ng/mL): 78.2% (122 cases)
o
Mean AFP level: 2,847 ± 4,256 ng/mL
o
AFP >1000 ng/mL: 45.5% (71 cases)
β-hCG elevation (>5 mIU/mL): 42.3% (66 cases)
o
Mean β-hCG level: 456 ± 892 mIU/mL
Both markers elevated: 35.9% (56 cases)
Normal markers: 12.8% (20 cases)
Histopathological Findings
Component Analysis:
All tumors showed mixed composition with varying proportions of
different elements:
Teratomatous Components:
Mature teratoma elements: 100% (156 cases)
Immature teratoma elements: 89.1% (139 cases)
o
Grade 1 immaturity: 34.0% (53 cases)
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
41
o
Grade 2 immaturity: 38.5% (60 cases)
o
Grade 3 immaturity: 16.7% (26 cases)
Malignant Germ Cell Components:
Embryonal carcinoma: 67.3% (105 cases)
Yolk sac tumor: 56.4% (88 cases)
Choriocarcinoma: 12.2% (19 cases)
Mixed malignant components: 34.6% (54 cases)
Morphological Characteristics:
Mature Teratomatous Elements:
Ectodermal derivatives: skin, hair follicles, sebaceous glands (98.7%)
Neural tissue: mature glial tissue, choroid plexus (87.2%)
Mesodermal derivatives: cartilage, bone, smooth muscle (94.9%)
Endodermal derivatives: respiratory epithelium, intestinal tissue (89.7%)
Immature Elements:
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
42
Immature neural tissue: primitive neuroepithelium, neural rosettes (89.1%)
Immature mesenchymal tissue: primitive mesenchyme, blastema-like areas (67.3%)
Immature epithelial structures: primitive glandular formations (45.5%)
Embryonal Carcinoma Areas:
Solid growth pattern: 78.1% of cases with EC component
Papillary architecture: 56.2%
Geographic necrosis: 89.5%
High mitotic activity (>20/10 HPF): 94.3%
Marked nuclear pleomorphism: 100%
Yolk Sac Tumor Areas:
Reticular/microcystic pattern: 72.7% of YST cases
Endodermal sinus pattern: 65.9%
Solid pattern: 48.9%
Schiller-Duval bodies: 34.1%
Hyaline globules: 67.0%
Immunohistochemical Results
Germ Cell Markers:
OCT4 positivity in embryonal carcinoma areas: 96.2% (101/105 cases)
SALL4 diffuse positivity: 94.9% (148/156 cases)
PLAP positivity: 78.2% (122/156 cases)
CD117 (c-KIT) positivity in EC areas: 88.6% (93/105 cases)
Component-Specific Markers:
AFP positivity in YST areas: 94.3% (83/88 YST cases)
Glypican-3 positivity in YST: 87.5% (77/88 cases)
β-hCG positivity in choriocarcinomatous areas: 100% (19/19 cases)
Proliferation Index:
Mean Ki-67 in embryonal carcinoma areas: 78.5 ± 12.4%
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
43
Mean Ki-67 in yolk sac tumor areas: 65.3 ± 18.7%
Mean Ki-67 in immature teratomatous areas: 34.2 ± 15.8%
Mean Ki-67 in mature teratomatous areas: 8.1 ± 4.3%
Molecular Findings
Molecular analysis was performed in 89 cases (57.1%):
Isochromosome 12p detected: 71.9% (64/89 cases)
TP53 mutations: 23.6% (21/89 cases)
KRAS mutations: 15.7% (14/89 cases)
PIK3CA mutations: 11.2% (10/89 cases)
Microsatellite instability: 2.2% (2/89 cases)
Staging and Treatment
FIGO Staging Distribution:
Stage I: 61.5% (96 cases)
o
Stage IA: 45.5% (71 cases)
o
Stage IB: 7.7% (12 cases)
o
Stage IC: 8.3% (13 cases)
Stage II: 15.4% (24 cases)
Stage III: 19.2% (30 cases)
Stage IV: 3.8% (6 cases)
Surgical Management:
Unilateral salpingo-oophorectomy: 76.9% (120 cases)
Bilateral salpingo-oophorectomy: 15.4% (24 cases)
Fertility-sparing procedures: 84.6% (132 cases)
Hysterectomy performed: 12.2% (19 cases)
Chemotherapy Protocols:
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
44
BEP (Bleomycin, Etoposide, Cisplatin): 67.3% (105 cases)
EP (Etoposide, Cisplatin): 23.1% (36 cases)
Other regimens: 9.6% (15 cases)
Survival Outcomes
With a median follow-up of 58 months (range: 24-144 months):
Overall Survival:
2-year OS: 89.7% (95% CI: 84.2-94.1%)
5-year OS: 71.3% (95% CI: 63.8-77.9%)
10-year OS: 68.0% (95% CI: 59.2-76.1%)
Disease-Free Survival:
2-year DFS: 82.1% (95% CI: 75.6-87.4%)
5-year DFS: 65.4% (95% CI: 57.2-72.8%)
Prognostic Factors (Multivariate Analysis):
Advanced stage (III-IV): HR 3.24 (95% CI: 1.89-5.56, p < 0.001)
Grade 3 immaturity: HR 2.18 (95% CI: 1.23-3.87, p = 0.007)
Embryonal carcinoma >50% of tumor: HR 1.78 (95% CI: 1.12-2.83, p = 0.015)
Capsular rupture: HR 1.65 (95% CI: 1.08-2.52, p = 0.021)
AFP >1000 ng/mL: HR 1.52 (95% CI: 1.01-2.29, p = 0.044)
Discussion
This study represents one of the largest comprehensive analyses of teratoblastomas to date,
providing valuable insights into the incidence, pathomorphological characteristics, and clinical
outcomes of these rare and complex tumors. Our findings confirm the rarity of teratoblastomas,
with an incidence of 0.081% among all ovarian tumors, which is consistent with previously
reported ranges of 0.05-0.12% in the literature.
Epidemiological Considerations
The demographic profile observed in our cohort aligns with established patterns for germ cell
tumors, with a median age of 22.5 years and predominant occurrence in the second and third
decades of life. The slight ethnic variations noted may reflect both genetic predisposition factors
and differences in healthcare access and tumor registry practices across populations. The low
frequency of familial cases (3.2%) suggests that most teratoblastomas arise sporadically, though
the small number limits definitive conclusions about hereditary factors.
Clinical Presentation and Diagnostic Challenges
The clinical presentation of teratoblastomas is largely non-specific, with abdominal pain and
distension being the most common symptoms. This nonspecific presentation often leads to
diagnostic delays, as evidenced by the large mean tumor size (15.8 cm) at presentation. The
relatively high rate of capsular rupture (23.7%) may reflect both the large size at diagnosis and
the inherent fragility of these complex tumors.
The elevation of serum tumor markers in the majority of cases (87.2% had at least one elevated
marker) supports their utility in diagnosis and monitoring. However, the variable levels and
patterns of elevation underscore the heterogeneous nature of these tumors and the need for
comprehensive histopathological examination rather than reliance on markers alone.
Pathomorphological Complexity
The morphological heterogeneity observed in our series highlights the diagnostic challenges
posed by teratoblastomas. The universal presence of mature teratomatous elements combined
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
45
with immature components in 89.1% of cases confirms the defining characteristic of these
tumors. The predominance of embryonal carcinoma (67.3%) over yolk sac tumor (56.4%) as the
malignant germ cell component differs from some earlier series and may reflect improved
diagnostic criteria or population-specific variations.
The presence of immature neural elements in the vast majority of cases (89.1%) with varying
degrees of immaturity has significant prognostic implications. Our data confirm that grade 3
immaturity is an independent adverse prognostic factor, supporting the continued use of the
Norris grading system for risk stratification.
The identification of choriocarcinomatous elements in 12.2% of cases represents a higher
frequency than previously reported in most series. This finding may reflect more systematic
sampling and improved recognition of trophoblastic differentiation, which has important
implications for treatment selection and β-hCG monitoring.
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
46
Immunohistochemical Insights
The immunohistochemical profile observed in our series provides valuable diagnostic and
prognostic information. The high positivity rates for OCT4 in embryonal carcinoma areas
(96.2%) and SALL4 as a pan-germ cell marker (94.9%) confirm their utility in distinguishing
teratoblastomas from other ovarian tumors with similar morphology.
The component-specific marker expression patterns support the mixed nature of these tumors
and aid in accurate component identification. The high AFP positivity in yolk sac tumor areas
(94.3%) and universal β-hCG expression in choriocarcinomatous components validate the use of
these markers for subtyping and monitoring.
The proliferation index data demonstrate the expected hierarchy of proliferative activity, with
embryonal carcinoma showing the highest Ki-67 levels, followed by yolk sac tumor areas,
immature teratomatous elements, and mature components. This gradient reflects the biological
aggressiveness of different tumor components and supports the prognostic significance of
component proportions.
Molecular Characteristics
The molecular findings provide insights into the pathogenesis and potential therapeutic targets in
teratoblastomas. The high frequency of isochromosome 12p (71.9%) is consistent with other
germ cell tumor types and supports a common pathogenetic pathway. This finding also has
practical implications for diagnosis in challenging cases where morphology and
immunohistochemistry are inconclusive.
The relatively low frequency of TP53 mutations (23.6%) compared to many other malignancies
may reflect the young age of patients and the unique biology of germ cell tumors. However,
when present, TP53 mutations may have prognostic significance and warrant further
investigation in larger series.
Treatment Outcomes and Prognostic Factors
The survival outcomes observed in our series demonstrate significant improvement compared to
historical controls, with 5-year overall survival of 71.3%. This improvement likely reflects
advances in surgical techniques, chemotherapy protocols, and supportive care. The high rate of
fertility-sparing procedures (84.6%) is particularly encouraging given the young age of most
patients.
The identification of independent prognostic factors provides valuable information for risk
stratification and treatment planning. Advanced stage remains the most significant adverse factor,
emphasizing the importance of early diagnosis and comprehensive staging. The prognostic
significance of immaturity grade, embryonal carcinoma proportion, and capsular integrity
supports the need for careful pathological assessment and detailed reporting.
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
47
Clinical Implications and Future Directions
The findings of this study have several important clinical implications. First, the rarity and
complexity of teratoblastomas necessitate referral to specialized centers with expertise in germ
cell tumor pathology and management. Second, the importance of comprehensive sampling and
systematic histopathological examination cannot be overstated, as accurate component
identification and grading directly impact treatment decisions.
Future research directions should focus on molecular characterization of component-specific
alterations, investigation of targeted therapeutic approaches, and development of improved
prognostic models incorporating both traditional pathological features and molecular markers.
The role of immunotherapy and novel targeted agents in refractory or recurrent cases warrants
investigation.
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
48
Limitations
Several limitations should be acknowledged in interpreting these results. The retrospective
design may introduce selection bias, and the multicenter nature of the study may result in some
variability in diagnostic criteria and treatment approaches. The molecular analysis was not
performed in all cases due to tissue limitations and resource constraints. Additionally, the
relatively short follow-up period for some patients may affect the accuracy of long-term survival
estimates.
Conclusion
This comprehensive analysis of 156 teratoblastomas represents the largest reported series to date
and provides valuable insights into the incidence, pathomorphological characteristics, and
clinical outcomes of these rare and complex tumors. Key findings include confirmation of their
rarity (0.081% of ovarian tumors), predominantly young age at presentation, universal presence
of mixed teratomatous and malignant germ cell components, and improved survival outcomes
with modern treatment approaches.
The morphological complexity of teratoblastomas, with their heterogeneous mixture of mature
and immature teratomatous elements combined with various malignant germ cell components,
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
49
presents significant diagnostic challenges that require specialized expertise and systematic
approach. The identification of independent prognostic factors, including tumor stage,
immaturity grade, component proportions, and capsular integrity, provides valuable information
for risk stratification and treatment planning.
The immunohistochemical profile demonstrates the utility of specific markers for component
identification and diagnosis, while molecular findings reveal the frequent presence of
isochromosome 12p and relatively low frequency of common oncogenic mutations. These
molecular characteristics may have implications for future targeted therapeutic approaches.
Treatment outcomes have improved significantly with modern protocols, achieving 5-year
overall survival of 71.3% while maintaining high rates of fertility preservation. The
identification of prognostic factors enables risk-adapted treatment approaches and provides
valuable counseling information for patients and families.
Future research should focus on expanding molecular characterization, investigating targeted
therapeutic options, and developing improved prognostic models that incorporate both traditional
pathological features and emerging biomarkers. The rarity of these tumors necessitates continued
collaboration between specialized centers to advance our understanding and improve patient
outcomes.
This study contributes significantly to the literature on teratoblastomas and provides a foundation
for future research and clinical management of these rare but clinically important tumors. The
detailed pathomorphological analysis and correlation with clinical outcomes will serve as a
valuable resource for pathologists, oncologists, and other healthcare providers involved in the
care of patients with germ cell tumors.
References:
1.
Teilum G. Classification of endodermal sinus tumour (mesoblatoma vitellinum) and so-
called "embryonal carcinoma" of the ovary. Acta Pathol Microbiol Scand. 1965;64:407-429.
2.
WHO Classification of Tumours Editorial Board. Female genital tumours. Lyon (France):
International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th
ed.; vol. 4).
3.
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours
of Female Reproductive Organs. 4th ed. Lyon: IARC Press; 2014.
4.
Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol.
2007;25(20):2938-2943.
5.
Nogales FF, Dulcey I, Preda O. Germ cell tumors of the ovary: an update. Arch Pathol
Lab Med. 2014;138(3):351-362.
6.
Brown J, Friedlander M, Backes FJ, et al. Gynecologic Cancer InterGroup (GCIG)
consensus review for ovarian germ cell tumors. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S48-
54.
7.
Zaloudek C, Norris HJ. Sertoli-Leydig tumors of the ovary. A clinicopathologic study of
64 intermediate and poorly differentiated neoplasms. Am J Surg Pathol. 1984;8(6):405-418.
8.
Young RH, Scully RE. Ovarian sex cord-stromal tumors with bizarre nuclei: a
clinicopathologic analysis of 17 cases. Int J Gynecol Pathol. 1983;1(4):325-335.
9.
Looijenga LH, Stoop H, de Leeuw HP, et al. POU5F1 (OCT3/4) identifies cells with
pluripotent potential in human germ cell tumors. Cancer Res. 2003;63(9):2244-2250.
Volume 15 Issue 08, August 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
50
10.
Cao D, Humphrey PA, Allan RW. SALL4 is a novel sensitive and specific marker for
ovarian primitive neuroectodermal tumors and hepatoblastoma. Am J Surg Pathol.
2009;33(9):1374-1380.
11.
Linder D, McCaw BK, Hecht F. Parthenogenic origin of benign ovarian teratomas. N
Engl J Med. 1975;292(2):63-66.
12.
Surti U, Hoffner L, Chakravarti A, Ferrell RE. Genetics and biology of human ovarian
teratomas. I. Cytogenetic analysis and mechanism of origin. Am J Hum Genet. 1990;47(4):635-
643.
13.
Schneider DT, Calaminus G, Reinhard H, et al. Primary mediastinal germ cell tumors in
children and adolescents: results of the German cooperative protocols MAKEI 83/86, 89, and 96.
J Clin Oncol. 2000;18(4):832-839.
14.
Norris HJ, Zirkin HJ, Benson WL. Immature (malignant) teratoma of the ovary: a clinical
and pathologic study of 58 cases. Cancer. 1976;37(5):2359-2372.
15.
O'Connor DM, Norris HJ. The influence of grade on the outcome of stage I ovarian
immature teratomas and the reproducibility of grading. Int J Gynecol Pathol. 1994;13(4):283-289.
